<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-45651" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Caspofungin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dongmo Fotsing</surname>
            <given-names>Laurena N.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bajaj</surname>
            <given-names>Tushar</given-names>
          </name>
          <aff>University of Chicago</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Laurena Dongmo Fotsing declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tushar Bajaj declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-45651.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Caspofungin is a medication within the echinocandins class designed to enhance the management of a spectrum of medical conditions. This comprehensive program discusses the intricacies of caspofungin's application, addressing conditions ranging from febrile neutropenia to various candida infections, invasive candidiasis, esophageal candidiasis, and invasive aspergillosis. Healthcare professionals will gain an in-depth understanding of caspofungin while covering crucial aspects such as its mechanism of action and adverse reactions profile, in addition to essential factors like off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions. Using this comprehensive knowledge, participants will be better equipped to make informed decisions and optimize patient outcomes when using caspofungin to manage and treat specified conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify clinical scenarios and fungal infections where caspofungin is indicated, recognizing its role as a first-line or alternative therapy based on evidence.</p></list-item><list-item><p>Differentiate between caspofungin and other antifungal agents, understanding their unique mechanisms of action, pharmacodynamics, and pharmacokinetics.</p></list-item><list-item><p>Assess patients receiving caspofungin, evaluate therapeutic responses, monitor for adverse reactions, and adjust treatment plans as needed.</p></list-item><list-item><p>Develop effective communication&#x000a0;with patients about caspofungin therapy's indications, benefits, and potential risks, ensuring informed decision-making.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=45651&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=45651">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-45651.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Caspofungin acetate is the first antifungal medication of the echinocandins class to receive marketing approval from the Food and Drug Administration (FDA).&#x000a0;Caspofungin was introduced in 2001 and approved for use in adults and pediatric patients (3 months and older).<xref ref-type="bibr" rid="article-45651.r1">[1]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Febrile neutropenia:<bold>&#x000a0;</bold>This condition is defined as a fever over 101 &#x000b0;F (or 38 &#x000b0;C) for 1 hour, with either an absolute neutrophil count (ANC) of less than or equal to 500 cells/&#x003bc;L or, alternately, an ANC of below or equal to 1000 cells/&#x003bc;L with a projected nadir of under or equal to 500 cells/&#x003bc;L. According to the Infectious Diseases Society of America (IDSA), empiric antifungal therapy is recommended for high-risk patients with persistent febrile neutropenia despite broad-spectrum antibiotic therapy. These antifungals include caspofungin, among others.<xref ref-type="bibr" rid="article-45651.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Invasive candidiasis: In a double-blind, randomized trial that compared the efficacy of caspofungin with amphotericin B in patients with invasive endocarditis, the more favorable outcome occurred in 73.4% of caspofungin recipients as opposed to 61.7% of amphotericin B recipients.<xref ref-type="bibr" rid="article-45651.r3">[3]</xref> For the initial treatment of candidemia, the echinocandins are preferred agents over azoles under the following conditions: identification or suspicion of either <italic toggle="yes">C. glabrata</italic> or <italic toggle="yes">C. krusei</italic>&#x000a0;or the patient&#x02019;s candidemia was refractory to treatment with an azole agent.<xref ref-type="bibr" rid="article-45651.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Candida infections: candidemia, intra-abdominal abscesses, peritonitis, and pleural space infections</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Esophageal candidiasis: Several studies have found caspofungin to have a favorable treatment response comparable to fluconazole.<xref ref-type="bibr" rid="article-45651.r5">[5]</xref><xref ref-type="bibr" rid="article-45651.r6">[6]</xref>&#x000a0;A year after the introduction of caspofungin in 2002, Villanueva et al conducted a double-blind, randomized trial with 177 HIV patients diagnosed with esophageal candidiasis. Researchers randomly assigned patients to&#x000a0;2 groups: caspofungin (50 mg IV) or fluconazole (200 mg IV), once daily for 7 to 21 days. There was a combined response of symptom resolution and significant endoscopic improvement 5 to 7 days after treatment discontinuation. The treatment response was 81% and 85% for the patients in each group, caspofungin and fluconazole, respectively.<xref ref-type="bibr" rid="article-45651.r5">[5]</xref>&#x000a0;The same year, a retrospective analysis performed by Kartsonis et al demonstrated the effectiveness of caspofungin in fluconazole-resistant or refractory esophageal candidiasis. The treatment was successful in 11 of the 14 patients with in-vitro-resistant isolates and 7 of the 11 patients with refractory disease. The use of caspofungin also appears to be associated with less toxic effects than IV amphotericin B in managing esophageal candidiasis.<xref ref-type="bibr" rid="article-45651.r6">[6]</xref><xref ref-type="bibr" rid="article-45651.r7">[7]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Invasive aspergillosis: Caspofungin has FDA approval to treat invasive aspergillosis in patients who are refractory to or intolerant of voriconazole, the primary antifungal agent.<xref ref-type="bibr" rid="article-45651.r1">[1]</xref><xref ref-type="bibr" rid="article-45651.r8">[8]</xref><xref ref-type="bibr" rid="article-45651.r9">[9]</xref>&#x000a0;Echinocandins are not recommended as first-line therapy.<xref ref-type="bibr" rid="article-45651.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Candida</italic>
<italic toggle="yes">spp</italic>&#x000a0;osteomyelitis or infectious arthritis</p>
          </list-item>
          <list-item>
            <p>Oropharyngeal candidiasis (thrush)</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Candida spp</italic>&#x000a0;cardiovascular system infections such as endocarditis and suppurative thrombophlebitis</p>
          </list-item>
          <list-item>
            <p>Candidiasis prophylaxis and aspergillosis prophylaxis in high-risk patients</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-45651.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Caspofungin, along with other echinocandins, works by noncompetitive inhibition of the enzyme &#x003b2;-(1,3)-D-glucan synthase, a critical component&#x000a0;in the synthesis of the fungal cell wall; this enzyme is not present in mammalian cells.<xref ref-type="bibr" rid="article-45651.r10">[10]</xref>&#x000a0;</p>
        <p>Caspofungin exhibits fungicidal activity against <italic toggle="yes">Candida</italic> species, including triazole-resistant isolates, and fungistatic activity against <italic toggle="yes">Aspergillus</italic> species.<xref ref-type="bibr" rid="article-45651.r1">[1]</xref><xref ref-type="bibr" rid="article-45651.r10">[10]</xref>&#x000a0;Caspofungin displays triphasic nonlinear pharmacokinetics. After an initial intravenous administration of the drug, there is a rapid decrease in plasma concentrations due to tissue distribution. This is followed by a gradual re-release of the drug from the extravascular tissues and slow hepatic metabolism.<xref ref-type="bibr" rid="article-45651.r11">[11]</xref><xref ref-type="bibr" rid="article-45651.r12">[12]</xref>&#x000a0;The drug undergoes hepatic metabolism via hydrolysis and slow N-acetylation into&#x000a0;2 inactive metabolites; dose reduction is advisable in severe hepatic insufficiency.<xref ref-type="bibr" rid="article-45651.r11">[11]</xref><xref ref-type="bibr" rid="article-45651.r12">[12]</xref><xref ref-type="bibr" rid="article-45651.r13">[13]</xref>&#x000a0;Caspofungin also&#x000a0;undergoes spontaneous disintegration to an open-ring compound.</p>
        <p>The pharmacokinetics of caspofungin also show an increased accumulation as the dose increases, and there is a dose-related dependency in the time to reach a steady state upon multiple-dose administration. Therefore, a loading dose followed by a lower once-daily dose is required to attain an initial therapeutic plasma concentration and avoid drug accumulation. This approach results in a trough concentration of at least 1 &#x003bc;g/mL (proposed target concentration in invasive infections derived from <italic toggle="yes">in vitro</italic> susceptibility testing of <italic toggle="yes">Candida</italic> spp).<xref ref-type="bibr" rid="article-45651.r13">[13]</xref><xref ref-type="bibr" rid="article-45651.r14">[14]</xref>&#x000a0;</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>
<bold>Absorption:</bold>
</p>
        <p>Caspofungin has negligible oral bioavailability (less than 0.2%) but has 92% tissue distribution within 36&#x000a0;to 48 hours after intravenous infusion.<xref ref-type="bibr" rid="article-45651.r15">[15]</xref></p>
        <p>
<bold>Distribution:</bold>
</p>
        <p>The drug is well distributed to tissues when administered intravenously, but it exhibits&#x000a0;a high level of protein binding (97%).</p>
        <p>
<bold>Metabolism:</bold>
</p>
        <p>Caspofungin is hepatically metabolized via chemical degradation by peptide hydrolysis and N-acetylation, with some CYP450 metabolism.&#x000a0;Caspofungin has a short &#x003b1;-phase half-life (t<sup>1/2</sup>) of 1 to 2 hours (volume of distribution of 9.7 L) and a &#x003b2;-phase t<sup>1/2</sup> of 9 to 11 hours that exhibits log linearity. Unlike the other phases, the &#x003b3;-phase t<sup>1/2</sup> of 40 to 50 hours appears nonlinear and responsible for caspofungin accumulation over time. Caspofungin is slowly eliminated from plasma, with a 10 to 12 mL/min clearance.<xref ref-type="bibr" rid="article-45651.r6">[6]</xref><xref ref-type="bibr" rid="article-45651.r13">[13]</xref></p>
        <p>
<bold>Elimination:</bold>
</p>
        <p>Approximately 75% of a radioactive dose is recovered after 27 days, with 41% in urine and 35% in feces. Only about 2% of caspofungin is excreted unchanged in the urine.<xref ref-type="bibr" rid="article-45651.r6">[6]</xref><xref ref-type="bibr" rid="article-45651.r13">[13]</xref></p>
      </sec>
      <sec id="article-45651.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosage Forms</bold>
</p>
        <p>Caspofungin acetate is administered solely by the intravenous (IV) route. Because the echinocandins have a large molecular weight, they are poorly bioavailable for oral use. The IV infusion should take place slowly over an hour and not be administered by IV bolus or mixed or co-infused with other medications. Do not use diluents containing dextrose (alpha-D-glucose).&#x000a0;</p>
        <p>The&#x000a0;available doses&#x000a0;include 50 and 70 mg per vial powder for injection containers.<xref ref-type="bibr" rid="article-45651.r12">[12]</xref>&#x000a0;The dosage varies by patient population.</p>
        <p>
<bold>Adult Dosing&#x000a0;</bold>
</p>
        <p>For all indications, administer an initial dose of 70 mg (loading dose) followed by 50 mg once IV daily. The daily dose may be increased to 70 mg if there is no response or if CYP3A4 inducers&#x000a0;such as&#x000a0;rifampin, nevirapine, efavirenz, carbamazepine, dexamethasone, and phenytoin&#x000a0;are coadministered. The maximum daily dose should not exceed 70 mg.</p>
        <p>For esophageal candidiasis, the dose is 50 mg once daily with no loading dose.</p>
        <p>
<bold>Special Population</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;The dosage for adult patients with&#x000a0;moderate hepatic impairment is reduced to 35 mg once daily, with a 70 mg loading dose on day&#x000a0;1 where appropriate.&#x000a0;Dose reduction for patients with hepatic insufficiency is recommended based on the Child-Pugh (C-P) score. However, in critically ill patients, the dose should not be reduced unless there is evidence of liver cirrhosis.<xref ref-type="bibr" rid="article-45651.r16">[16]</xref>&#x000a0;</p>
        <p><bold>Renal impairment:&#x000a0;</bold>No dose reduction is necessary for renal impairment; echinocandin passage through the membranes seems low because of high protein binding, 97% to albumin.<xref ref-type="bibr" rid="article-45651.r17">[17]</xref>&#x000a0;</p>
        <p><bold>Pregnant patients:&#x000a0;</bold>Clinicians should weigh the risks vs benefits in pregnant patients. No human data is available on this topic. Animal data indicates possible embryo-fetal toxicity.</p>
        <p><bold>Breastfeeding patients:&#x000a0;</bold>Patients may use the drug while breastfeeding; infant harm is not expected based on drug properties. There is no human data regarding caspofungin's effect on milk production.</p>
        <p><bold>Pediatric patients:&#x000a0;</bold>The basis for dosing is on the patient's body surface area.&#x000a0;For all indications, a single 70 mg/m<sup>2</sup> loading dose on day 1 will be followed by 50 mg/m<sup>2</sup> once daily.</p>
        <p><bold>Older patients:</bold>&#x000a0;Trials&#x000a0;performed to date have not revealed any data&#x000a0;that would limit the use of caspofungin injection in older patients.</p>
      </sec>
      <sec id="article-45651.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Caspofungin has a relatively low incidence of adverse effects; the most commonly reported include chills, fever, phlebitis/thrombophlebitis, tachycardia, nausea, vomiting, rash, abdominal pain, headache, and diarrhea.<xref ref-type="bibr" rid="article-45651.r6">[6]</xref>&#x000a0;Caspofungin can also increase AST and ALT levels.</p>
        <p>Caspofungin has been found to cause skin erosions similar to those seen in toxic epidermal necrolysis (TEN). A case report by Lee et al describes the development of a rash (erythematous macules and plaques) that quickly progressed to blisters and skin erosions after administering caspofungin in an 86-year-old man with disseminated <italic toggle="yes">Candida krusei</italic> infection.<xref ref-type="bibr" rid="article-45651.r18">[18]</xref>&#x000a0;Other rare but potentially severe reactions include Stevens-Johnson syndrome, septic shock, and erythema multiforme.</p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p>An increase in the maintenance dose of caspofungin is recommended with the coadministration of potent inducers of hepatic CYP3A4 enzymes. These agents include rifampin, nevirapine, efavirenz, carbamazepine, dexamethasone, and phenytoin.<xref ref-type="bibr" rid="article-45651.r6">[6]</xref>&#x000a0;Using caspofungin with CYP3A4 inducers, the daily dose may be increased to 70 mg. However, the maximum daily dose should not exceed 70 mg.</p>
        <p>Concomitant use of caspofungin with cyclosporine has also been&#x000a0;linked to increased caspofungin-induced hepatotoxicity. However, several case reports describe patients treated with both drugs without clinically important signs or symptoms of liver toxicity.<xref ref-type="bibr" rid="article-45651.r19">[19]</xref><xref ref-type="bibr" rid="article-45651.r20">[20]</xref><xref ref-type="bibr" rid="article-45651.r21">[21]</xref><xref ref-type="bibr" rid="article-45651.r22">[22]</xref>&#x000a0;Combined therapy with cyclosporin should be avoided as this combination could increase caspofungin levels and impact liver enzymes, increasing AST and ALT levels.</p>
      </sec>
      <sec id="article-45651.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The main contraindication to caspofungin therapy is a known hypersensitivity reaction to the formulation's caspofungin acetate or other ingredients. Caution is advised in patients with Child-Pugh Class C hepatic impairment.</p>
        <p>There is inadequate data regarding the use of caspofungin in pregnancy; clinicians should use the drug cautiously in&#x000a0;this patient population. When treatment of systemic fungal infections is necessary during pregnancy, Amphotericin B is the first-line therapy.<xref ref-type="bibr" rid="article-45651.r23">[23]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-45651.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Given caspofungin's potential hepatic adverse effects, monitoring liver function is essential.&#x000a0;Caspofungin is known to release histamine in peripheral blood cells, which predisposes patients to potentially developing histamine-mediated symptoms ranging from severe to fatal anaphylaxis. As a result, monitoring patients for anaphylaxis, rash, or histamine-related reactions (eg, facial swelling, bronchospasm, a sensation of warmth) is paramount to decreasing the risk of morbidity and mortality.<xref ref-type="bibr" rid="article-45651.r24">[24]</xref><xref ref-type="bibr" rid="article-45651.r25">[25]</xref><xref ref-type="bibr" rid="article-45651.r26">[26]</xref></p>
      </sec>
      <sec id="article-45651.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Hepatitis, hepatomegaly, and hyperbilirubinemia can rarely occur. There are also reports of hepatic failure with the echinocandins. Therefore, checking hepatic aminotransferases regularly during caspofungin therapy is recommended.<xref ref-type="bibr" rid="article-45651.r27">[27]</xref></p>
      </sec>
      <sec id="article-45651.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Caspofungin has significant therapeutic effects, evidenced by its safety profile and minimal drug interactions, but its use still requires the efforts of an engaged interprofessional healthcare team. These factors have led to its use in treating several medical conditions.<xref ref-type="bibr" rid="article-45651.r1">[1]</xref><xref ref-type="bibr" rid="article-45651.r8">[8]</xref>&#x000a0;However, it is essential to note the potential adverse effects of caspofungin despite their low incidence.<xref ref-type="bibr" rid="article-45651.r18">[18]</xref>&#x000a0;Monitoring patients&#x02019; liver function to minimize toxicity is also critical, given this organ metabolizes the drug. Furthermore, caspofungin is associated with some drug-drug interactions, especially CYP3A4 inducers, which cause caspofungin concentrations to become subtherapeutic.<xref ref-type="bibr" rid="article-45651.r6">[6]</xref>&#x000a0;Before prescribing caspofungin for patients who are taking several medications, the prescriber/ordering clinician should consult with the following team members:</p>
        <list list-type="bullet">
          <list-item>
            <p>The clinical pharmacist ensures that concomitant administration of the patient&#x02019;s medications and caspofungin is permissible. In drug-drug interactions, the clinical pharmacist should notify the prescribing physician, who can decide the appropriate course of action based on the patient&#x02019;s clinical findings and comorbidities.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The obstetrician-gynecologist&#x000a0;should provide input on the case for pregnant patients since the&#x000a0;use of caspofungin in pregnancy is currently not recommended in the United States.<xref ref-type="bibr" rid="article-45651.r23">[23]</xref>&#x000a0;The drug should only be administered to pregnant women if the potential benefit outweighs the potential risk to the fetus.<xref ref-type="bibr" rid="article-45651.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>Nursing staff will also play a significant role in inpatient administration, monitoring treatment effectiveness, checking for adverse effects of the medication, and reporting findings to the healthcare team.</p>
        <p>Ultimately, adopting an interprofessional team approach with collaboration with infectious disease physicians and other sub-specialties, primary care physicians, nurses, pharmacists, and other healthcare personnel is essential to facilitate the administration of the drugs based on current guidelines and maximize patient outcomes while minimizing adverse reactions.&#x000a0;</p>
      </sec>
      <sec id="article-45651.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=45651&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=45651">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/45651/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=45651">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-45651.s11">
        <title>References</title>
        <ref id="article-45651.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morris</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Villmann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Echinocandins in the management of invasive fungal infections, part 1.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2006</year>
            <month>Sep</month>
            <day>15</day>
            <volume>63</volume>
            <issue>18</issue>
            <fpage>1693</fpage>
            <page-range>1693-703</page-range>
            <pub-id pub-id-type="pmid">16960253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patterson</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Denning</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hadley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Herbrecht</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kontoyiannis</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Marr</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Steinbach</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Wingard</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Aug</month>
            <day>15</day>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>e1</fpage>
            <page-range>e1-e60</page-range>
            <pub-id pub-id-type="pmid">27365388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mora-Duarte</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Betts</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rotstein</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Thompson-Moya</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Smietana</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lupinacci</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sable</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kartsonis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Perfect</surname>
                <given-names>J</given-names>
              </name>
              <collab>Caspofungin Invasive Candidiasis Study Group</collab>
            </person-group>
            <article-title>Comparison of caspofungin and amphotericin B for invasive candidiasis.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Dec</month>
            <day>19</day>
            <volume>347</volume>
            <issue>25</issue>
            <fpage>2020</fpage>
            <page-range>2020-9</page-range>
            <pub-id pub-id-type="pmid">12490683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andes</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Safdar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Baddley</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Playford</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Reboli</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Rex</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sobel</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Kullberg</surname>
                <given-names>BJ</given-names>
              </name>
              <collab>Mycoses Study Group</collab>
            </person-group>
            <article-title>Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.</article-title>
            <source>Clin Infect Dis</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>8</issue>
            <fpage>1110</fpage>
            <page-range>1110-22</page-range>
            <pub-id pub-id-type="pmid">22412055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villanueva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gotuzzo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Arathoon</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Noriega</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Kartsonis</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Lupinacci</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Smietana</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>DiNubile</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sable</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.</article-title>
            <source>Am J Med</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>113</volume>
            <issue>4</issue>
            <fpage>294</fpage>
            <page-range>294-9</page-range>
            <pub-id pub-id-type="pmid">12361815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keating</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Figgitt</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.</article-title>
            <source>Drugs</source>
            <year>2003</year>
            <volume>63</volume>
            <issue>20</issue>
            <fpage>2235</fpage>
            <page-range>2235-63</page-range>
            <pub-id pub-id-type="pmid">14498760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kartsonis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>DiNubile</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bartizal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sable</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2002</year>
            <month>Oct</month>
            <day>01</day>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-7</page-range>
            <pub-id pub-id-type="pmid">12394797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morris</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Villmann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Echinocandins in the management of invasive fungal infections, Part 2.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2006</year>
            <month>Oct</month>
            <day>01</day>
            <volume>63</volume>
            <issue>19</issue>
            <fpage>1813</fpage>
            <page-range>1813-20</page-range>
            <pub-id pub-id-type="pmid">16990627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maertens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Raad</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Petrikkos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Boogaerts</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Selleslag</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Sable</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kartsonis</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Ngai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Denning</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>TJ</given-names>
              </name>
              <collab>Caspofungin Salvage Aspergillosis Study Group</collab>
            </person-group>
            <article-title>Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.</article-title>
            <source>Clin Infect Dis</source>
            <year>2004</year>
            <month>Dec</month>
            <day>01</day>
            <volume>39</volume>
            <issue>11</issue>
            <fpage>1563</fpage>
            <page-range>1563-71</page-range>
            <pub-id pub-id-type="pmid">15578352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sucher</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Chahine</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Balcer</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Echinocandins: the newest class of antifungals.</article-title>
            <source>Ann Pharmacother</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>10</issue>
            <fpage>1647</fpage>
            <page-range>1647-57</page-range>
            <pub-id pub-id-type="pmid">19724014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Winchell</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Deutsch</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Migoya</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Mistry</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Xi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>deLuna</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dilzer</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Lasseter</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>815</fpage>
            <page-range>815-23</page-range>
            <pub-id pub-id-type="pmid">14982770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Wickersham</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Sterrett</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bonfiglio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hesney</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Winchell</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Deutsch</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Waldman</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>739</fpage>
            <page-range>739-45</page-range>
            <pub-id pub-id-type="pmid">11850256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kofla</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ruhnke</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.</article-title>
            <source>Eur J Med Res</source>
            <year>2011</year>
            <month>Apr</month>
            <day>28</day>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>159</fpage>
            <page-range>159-66</page-range>
            <pub-id pub-id-type="pmid">21486730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Betts</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Nucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Talwar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gareca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Queiroz-Telles</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bedimo</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Herbrecht</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ruiz-Palacios</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Baddley</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Strohmaier</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Tucker</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Kartsonis</surname>
                <given-names>NA</given-names>
              </name>
              <collab>Caspofungin High-Dose Study Group</collab>
            </person-group>
            <article-title>A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2009</year>
            <month>Jun</month>
            <day>15</day>
            <volume>48</volume>
            <issue>12</issue>
            <fpage>1676</fpage>
            <page-range>1676-84</page-range>
            <pub-id pub-id-type="pmid">19419331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and safety of intravitreal caspofungin.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>58</volume>
            <issue>12</issue>
            <fpage>7234</fpage>
            <page-range>7234-9</page-range>
            <pub-id pub-id-type="pmid">25246398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurland</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Furebring</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>L&#x000f6;wdin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Eliasson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;lin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin Levels.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>63</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">30962329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pfisterer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stienecke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stippler</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Welte</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Joannidis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Griesmacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bellmann</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>57</volume>
            <issue>8</issue>
            <fpage>4053</fpage>
            <page-range>4053-7</page-range>
            <pub-id pub-id-type="pmid">23733471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Caspofungin-induced severe toxic epidermal necrolysis.</article-title>
            <source>Ann Pharmacother</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>1116</fpage>
            <page-range>1116-8</page-range>
            <pub-id pub-id-type="pmid">20407030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anttila</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Piilonen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valtonen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Co-administration of caspofungin and cyclosporine to a kidney transplant patient with pulmonary Aspergillus infection.</article-title>
            <source>Scand J Infect Dis</source>
            <year>2003</year>
            <volume>35</volume>
            <issue>11-12</issue>
            <fpage>893</fpage>
            <page-range>893-4</page-range>
            <pub-id pub-id-type="pmid">14723374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veroux</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Macarone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fiamingo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cappello</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gagliano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Mare</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vizcarra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spataro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giuffrida</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sorbello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Severino</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Veroux</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients.</article-title>
            <source>Transplant Proc</source>
            <year>2006</year>
            <month>May</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>1037</fpage>
            <page-range>1037-9</page-range>
            <pub-id pub-id-type="pmid">16757256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Candoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mestroni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Damiani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tiribelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Michelutti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Silvestri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Castelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Viale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fanin</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.</article-title>
            <source>Eur J Haematol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>75</volume>
            <issue>3</issue>
            <fpage>227</fpage>
            <page-range>227-33</page-range>
            <pub-id pub-id-type="pmid">16104879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Groetzner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaczmarek</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wittwer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Strauch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meiser</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wahlers</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Daebritz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reichart</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-6</page-range>
            <pub-id pub-id-type="pmid">18187079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moudgal</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Sobel</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Antifungal drugs in pregnancy: a review.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>475</fpage>
            <page-range>475-83</page-range>
            <pub-id pub-id-type="pmid">12946248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biswal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Complete heart block in a neutropenic patient with aspergillosis: An unusual adverse effect of caspofungins.</article-title>
            <source>J Pharmacol Pharmacother</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>342</fpage>
            <page-range>342-4</page-range>
            <pub-id pub-id-type="pmid">23326111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kounis</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>Caspofungin-induced fatal complete heart block: Another manifestation of Kounis syndrome.</article-title>
            <source>J Pharmacol Pharmacother</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-2</page-range>
            <pub-id pub-id-type="pmid">23761719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cleary</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>de Mestral</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Effects of amphotericin B and caspofungin on histamine expression.</article-title>
            <source>Pharmacotherapy</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>8</issue>
            <fpage>966</fpage>
            <page-range>966-73</page-range>
            <pub-id pub-id-type="pmid">12921242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-45651.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>ZC</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Adverse Effects Associated With Currently Commonly Used Antifungal Agents: A Network Meta-Analysis and Systematic Review.</article-title>
            <source>Front Pharmacol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>697330</fpage>
            <pub-id pub-id-type="pmid">34776941</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
